Why the David Protein CEO Says GLP-1 Drugs Have Ended the Era of Diet Trends

For decades the new year arrived with a predictable companion, the latest diet. Keto one winter, paleo the next, a parade of plans that food companies could set their calendars by. Peter Rahal, the founder and chief executive of David Protein, argues that whole cycle has quietly ended, and the reason is sitting in millions of medicine cabinets.

His verdict is blunt. Because of GLP-1 drugs, he says, diet trends are over. The point is not that people stopped wanting to change their bodies. It is that the tool they reach for has changed. No one is turning to a diet as the intervention anymore, in his telling. Everyone is turning to a prescription.

How GLP-1s rewrote the rules

The medications, which slow digestion and quiet appetite, are now used by roughly one in ten Americans, and the market for them is on track for around 82 billion dollars a year. That scale has consequences far beyond the pharmacy. When appetite suppression becomes a pill rather than a meal plan, the businesses built on meal plans lose their reason to exist. WeightWatchers, a name synonymous with dieting for generations, filed for Chapter 11 bankruptcy in 2025, undone in part by exactly this shift.

Rahal speaks with some authority on food cycles. Before David Protein, the bar and ice cream brand he launched in 2024, he built RXBar and sold it to Kellogg's for 600 million dollars. He has watched trends rise and fall, and he is convinced this one is different because it is medical rather than cultural.

The rise of proteinmaxxing

The drugs did not kill the appetite for self improvement, they redirected it. Because GLP-1 users eat less, they have to make every bite count, and the nutrient they cannot afford to skip is protein, which protects muscle as the weight comes off. The result is a craze Rahal has nicknamed protein capitalism, a market where protein stamped products crowd every shelf.

The evidence is everywhere, from Khloe Kardashian's Khloud protein popcorn to protein boosted drinks at Starbucks. As Rahal puts it, protein is popular fundamentally because it is GLP-1 driven, and that is also why what comes next is so hard to predict. The old fads were cultural and cyclical. This one is wired into how a drug works.

A supply chain under strain

All that demand has hit the raw materials hard. Whey protein concentrate, prized for its taste and stability, has spiked in price. USDA figures show high protein whey concentrate up about 40 percent in recent months, with some suppliers already tapped out. David Protein has felt it directly, with the whey it relies on climbing from around 7 dollars a pound to nearly 12 since late 2024.

The squeeze may force some manufacturers to reformulate around other protein sources, which could drain demand for whey while pushing up costs for the alternatives. Kathleen Wolfley, an agriculture consultant at Ever.Ag Insights, frames the underlying pull plainly, noting that people supplementing with GLP-1s need the extra protein to hold onto muscle and feel good, which keeps demand very firm.

Surviving the unpredictable

David Protein, for its part, is doing well despite the cost pressure. Its products sit in roughly 16,000 stores and are on pace for about 300 million dollars in annual revenue. Asked how the company is navigating the chaos, Rahal kept it simple. The strategy, he said, is just to survive rather than to change anything.

That modesty captures the strange moment the food industry finds itself in. For years the calendar did the forecasting. Now a class of drugs has scrambled the cycle, and even the people riding the protein wave admit they cannot see clearly past it.